Fundraising FoxMRL Ventures Fund — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMission BiocapitalNextech InvestRA Capital
Developing novel KRAS degraders.
Burlington, US
Huaixiang Hao(Founder)in
Co-investorsBioTrack CapitalJJDC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.